Molecular Basis for the Susceptibility of Fibrin-bound Thrombin to Inactivation by Heparin Cofactor II in the Presence of Dermatan Sulfate but Not Heparin*

Patricia C. Y. LiawDagger, Debra L. Becker, Alan R. Stafford, James C. Fredenburgh, and Jeffrey I. Weitz§

From McMaster University and the Henderson Research Centre, Hamilton, Ontario L8V 1C3, Canada

Received for publication, November 22, 2000, and in revised form, March 9, 2001


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Although fibrin-bound thrombin is resistant to inactivation by heparin·antithrombin and heparin·heparin cofactor II complexes, indirect studies in plasma systems suggest that the dermatan sulfate·heparin cofactor II complex can inhibit fibrin-bound thrombin. Herein we demonstrate that fibrin monomer produces a 240-fold decrease in the heparin-catalyzed rate of thrombin inhibition by heparin cofactor II but reduces the dermatan sulfate-catalyzed rate only 3-fold. The protection of fibrin-bound thrombin from inhibition by heparin·heparin cofactor II reflects heparin-mediated bridging of thrombin to fibrin that results in the formation of a ternary heparin·thrombin·fibrin complex. This complex, formed as a result of three binary interactions (thrombin·fibrin, thrombin·heparin, and heparin·fibrin), limits accessibility of heparin-catalyzed inhibitors to thrombin and induces conformational changes at the active site of the enzyme. In contrast, dermatan sulfate binds to thrombin but does not bind to fibrin. Although a ternary dermatan sulfate· thrombin·fibrin complex forms, without dermatan sulfate-mediated bridging of thrombin to fibrin, only two binary interactions exist (thrombin·fibrin and thrombin· dermatan sulfate). Consequently, thrombin remains susceptible to inactivation by heparin cofactor II. This study explains why fibrin-bound thrombin is susceptible to inactivation by heparin cofactor II in the presence of dermatan sulfate but not heparin.


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Heparin, a sulfated polysaccharide, acts as an anticoagulant by accelerating the inhibition of thrombin and factor Xa by antithrombin (1). Although heparin is widely used for the treatment of acute coronary ischemic syndromes, it has limitations in patients undergoing percutaneous coronary interventions (2) or when used as an adjunct to thrombolytic therapy (3-5). These limitations have been attributed to the inability of the antithrombin·heparin complex to inactivate clotting enzymes bound to components of the thrombus, particularly thrombin bound to fibrin (6, 7).

Resistance of fibrin-bound thrombin to inactivation by the antithrombin·heparin complex reflects the incorporation of thrombin into a ternary heparin·thrombin·fibrin complex (8-10). To form this complex, heparin interacts with both exosite II on thrombin (11-13) and the D domain of fibrin (14), thereby bridging thrombin to fibrin via exosite II (8). This heightens exosite I-mediated binding of thrombin to fibrin and likely increases the overall affinity of thrombin for fibrin. The formation of the ternary complex, therefore, is a consequence of the presence of two exosites on thrombin, which independently bind fibrin and heparin. Recently, we demonstrated that protection requires ligation of both of thrombin's exosites within the ternary heparin·thrombin·fibrin complex, a process that impairs access of inhibitor-bound heparin to exosite II on thrombin (15). Thrombin within the ternary complex is protected from inactivation by the heparin·heparin cofactor II (HCII)1 complex to a greater extent than the heparin·antithrombin complex (15), because access of the amino terminus of HCII to exosite I on thrombin, an obligatory part of the HCII inhibitory mechanism (16, 17), is reduced. Allosteric changes in the active site of thrombin induced upon formation of the ternary heparin·thrombin·fibrin complex may also contribute to the protection of fibrin-bound thrombin from inactivation by heparin·antithrombin and heparin·HCII complexes by limiting inhibitor reactivity with fibrin-bound thrombin (18).

Dermatan sulfate (DS), a sulfated glycosaminoglycan that has antithrombotic activity in laboratory animals (19, 20) and in humans (21-23), acts as an anticoagulant by catalyzing only HCII. Because thrombin is the exclusive plasma target of HCII, DS is considered a selective inhibitor of thrombin (16). Although fibrin-bound thrombin is protected from inactivation by the heparin·HCII complex (15), indirect studies done in plasma systems suggest that fibrin-bound thrombin is susceptible to inactivation by the DS·HCII complex (24, 25). The purpose of this study was to confirm these findings using purified reagents and to elucidate the mechanism by which the DS·HCII complex, but not the heparin·HCII complex, inactivates fibrin-bound thrombin.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Materials

Human HCII, isolated from plasma by affinity chromatography, was from Affinity Biologicals Inc. (Hamilton, Ontario, Canada). Human alpha - and gamma -thrombin and fibrinogen were from Enzyme Research Laboratories (South Bend, IN). Dermatan sulfate (DS) was from Mediolanum Farmaceutici (Milan, Italy). Heparin, N-p-tosyl-Gly-Pro-Arg-p-nitroanilide acetate (tGPR-pNA), gelatin-agarose, and Gly-Pro-Arg-Pro-amide (GPRP-NH2) were from Sigma Chemical Co. (St. Louis, MO). Enoxaparin, a commercial low-molecular-weight heparin, was from Rhône-Poulenc Rorer Canada (Montreal). Based on high performance liquid chromatography gel filtration analysis, the mean molecular masses of DS, heparin, and enoxaparin are 20 kDa (range 7-34 kDa), 15 kDa (range 5-30 kDa), and 4.5 kDa (range 3.5-5.5 kDa), respectively. Fluorescein-5'-isothiocyanate (FITC) was from Molecular Probes Inc. (Eugene, OR). D-Phe-Pro-Arg-chloromethyl ketone (FPRCK) was from Calbiochem Novabiochem Corp. (San Diego, CA). FITC-FPRCK was from Hematologic Technologies, Inc. (Essex Junction, VT). Hexadimethrine bromide (Polybrene) was obtained from Aldrich Chemical Co. (Milwaukee, WI). Cyanogen bromide-activated Sepharose 4B was from Amersham Pharmacia Biotech (Dorval, Quebec).

Preparation of Soluble Fibrin-- Human fibrinogen, treated with gelatin-agarose to remove fibronectin, was used to prepare soluble fibrin (SF), as described previously (15). Briefly, fibrin clots were centrifuged and dialyzed versus water. The fibrin was then dissolved by dialysis versus 20 mM acetic acid, aliquoted, and stored at a concentration of about 100 µM at -70 °C. Polymerization of SF was blocked by addition of 5 mM GPRP-NH2 (26), and the material was neutralized with 1 M Tris-HCl, pH 7.5, in a volume corresponding to 40% of the volume of SF, just prior to use. A molecular weight of 340,000 and epsilon <UP><SUB>280</SUB><SUP>1%</SUP></UP> value of 14.0 were used to calculate the soluble fibrin concentration.

Preparation of Fibrin Monomer-Sepharose-- Fibrinogen was coupled to cyanogen bromide-activated Sepharose 4B, treated with thrombin to convert it to fibrin monomer (FM), and washed with 20 mM Tris-HCl, pH 7.4, 150 nM NaCl (TBS) as described previously (15).

Methods

Rates of Thrombin Inhibition by HCII in the Absence or Presence of SF, Glycosaminoglycans, or Both-- The influence of varying concentrations of heparin or DS on the second-order rate constants (k2) for inhibition of thrombin by HCII were determined under pseudo-first-order conditions in the absence or presence of SF. Thrombin (10 nM) was incubated for 5 min at room temperature in TBS containing 0.6% PEG 8000 in the presence of various concentrations of heparin or DS (0-11 µM), SF (0-4 µM), and 10 mM GPRP-NH2. Reaction mixtures (10 µl) were aliquoted to 96-well round bottom microtiter plates and an equal volume of HCII (in a concentration at least 10-fold higher than that of thrombin) was added to each well at time intervals ranging from 2 s to 5 min. All reactions were terminated concomitantly by the addition of 200 µM chromogenic substrate (tGPR-pNA) in 200 µl of TBS containing 10 mg/ml Polybrene. Residual thrombin activity was calculated by measuring absorbance at 405 nm for 5 min using a Spectra Max 340 Microplate Reader (Molecular Devices, Menlo Park, CA). The pseudo-first-order rate constants (k1) for thrombin inhibition were determined by fitting the data to the equation k1·t = ln([P]o/[P]t), where [P]o is initial thrombin activity and [P]t is thrombin activity at time t. The second-order rate constant, k2, was then determined by dividing k1 by the HCII concentration (27).

Effect of Heparin and DS on the Binding of 125I-FPR-thrombin to FM-Sepharose-- Thrombin blocked at its active site with FPRCK (FPR-thrombin) was radiolabeled with Na125I as described previously (28). The binding of 125I-FPR-thrombin to FM-Sepharose in the absence or presence of either heparin or DS (from 0 to 10 µM) was studied in TBS containing 0.6% PEG 8000 and 0.01% Tween 20. FM-Sepharose (9 µM) in 0.5 ml of buffer was incubated with 50 nM 125I-FPR-thrombin by inverted mixing for 2 min. The tube was centrifuged in a microcentrifuge for 2 min at 15,000 × g, and a 100-µl aliquot of supernatant was removed for gamma counting. The aliquot was returned to the tube. This procedure was repeated following each addition of heparin or DS to the tube. The fraction of 125I-FPR-thrombin bound to FM-Sepharose as a function of the total amount of 125I-FPR-thrombin present was calculated.

Effect of Thrombin or gamma -Thrombin on the Binding of 125I-Labeled DS to FM-Sepharose-- DS (3 mg) was labeled with 1.0 mCi of Na125I (PerkinElmer Life Sciences, Markham, Ontario, Canada) in a volume of 300 µl using the IODO-BEAD iodination reagent as described by the manufacturer (Pierce, Rockford, IL). Labeled DS catalyzed the inhibition of thrombin by HCII to the same extent as its unlabeled counterpart, indicating that the labeling procedure did not influence DS activity. A mixture of 500 nM 125I-labeled DS and 5 µM FM-Sepharose was titrated with increasing concentrations of thrombin or gamma -thrombin (from 0 to 3 µM). After centrifugation, residual 125I-labeled DS in the supernatant was quantified by gamma counting and used to determine the fraction of 125I-labeled DS bound to FM-Sepharose.

Effect of Ternary Thrombin·Fibrin·Heparin or Thrombin·Fibrin·DS Complex Formation on the Active Site Environment of Thrombin-- Thrombin labeled at the active site with anilinonaphthalene-6-sulfonic acid (ANS-FPR-thrombin) was prepared using ATA-FPR (N-(acetylthio)acetyl-D-Phe-Pro-Arg-CH2Cl) as described by the supplier (Molecular Innovations Inc., Royal Oak, MI). Briefly, 10.6 µM thrombin was incubated for 30 min at 23 °C with a 2.5-fold molar excess of ATA-FPR in 20 mM HEPES-NaOH, pH 7.0, 100 mM NaCl, 1 mM EDTA (HBSE buffer). The reaction mixture was dialyzed against HBSE buffer, incubated with a 10-fold molar excess of 2-(4-(iodoacetamide)anilino)naphthalene-6-sulfonic acid (Molecular Probes Inc.) in the presence of hydroxylamine for 60 min at 23 °C in the dark and then redialyzed. 800 µl of 140 nM ANS-FPR-thrombin in 50 mM HEPES, pH 7.5, 0.125 M NaCl, 1 mg/ml PEG 8000, 5 mM GPRP-NH2 was added to a semi-micro quartz cuvette. Using a PerkinElmer Life Sciences LS50B luminescence spectrometer with excitation wavelength set to 334 nm and excitation and emission slit widths set to 5 nm, the fluorescence emission spectrum from 380-580 nm of ANS-FPR-thrombin was monitored before and after the addition of 310 nM SF and/or 100 nM heparin or 3 µM DS. Soluble fibrin was neutralized by the addition of 40% v/v M Tris-HCl, pH 7.5, just prior to use. Addition of 1 M Tris-HCl, pH 7.5, had no effect on the fluorescence spectrum of ANS-FPR-thrombin (data not shown).

Determination of the Affinities of f-heparin, f-DS, and f-FPR-thrombin for Fibrin Clots-- Fluorescent derivatives of heparin and DS were prepared as follows (29). 10 mg of heparin or DS were incubated with 15 mg of FITC in 2.5 ml of 1.0 M Na2CO3, pH 9.0 for 5 h at 23 °C. After centrifugation at 13,000 × g for 5 min, 1 ml of the supernatant was applied to duplicate PD-10 gel filtration columns (Millipore Corp., Bedford, MA), equilibrated with H2O, and eluted with H2O under gravity. 0.5-ml fractions were collected, frozen, and lyophilized. Recovered material was pooled, weighed, and dissolved in TBS to a stock concentration of 10 mg/ml. FITC-labeled active site-blocked thrombin (f-FPR-thrombin) was prepared as previously described (28). Briefly, thrombin was incubated with fluorescein-D-Phe-Pro-Arg chloromethyl ketone (f-FPRCK) until no residual thrombin chromogenic activity was detected. After dialysis to remove unincorporated f-FPRCK, the concentration of fluorescently labeled thrombin was determined by measuring absorbance using epsilon <UP><SUB>280</SUB><SUP>1%</SUP></UP> of 1.8 after correction for light scatter at 320 nm using the relationship A<UP><SUB>280</SUB><SUP>corr</SUP></UP> =A280 - 1.7 × A320.

The affinity of FITC-labeled ligands for fibrin was determined by measuring unbound ligand in supernatants of clots prepared by clotting varying concentrations of fibrinogen with 1 nM thrombin. Briefly, 200 µl of 2 mM CaCl2, 100 nM FITC-labeled ligand, various concentrations of fibrinogen (30-3000 nM), and 1 nM thrombin were mixed in a series of microcentrifuge tubes. After 1-h incubation at 23 °C, fibrin was pelleted by centrifugation for 5 min at 15,000 × g and 100 µl of supernatant was removed and added to 300 µl of TBS. The fluorescence intensity of the samples was monitored with excitation and emission wavelengths set to 492 and 522 nm, respectively, and excitation and emission slit widths both set to 15 nm. Kd values were calculated by plotting I/Io versus fibrinogen concentration, where Io and I represent the fluorescence intensities in the absence and presence of the varying concentrations of fibrinogen, respectively. The parameters Kd and Delta I were calculated by nonlinear regression ("Tablecurve," Jandel Scientific, San Rafael, CA) using the equation,
<FR><NU>I</NU><DE>I<SUB>0</SUB></DE></FR>=1+<FENCE>1+<FR><NU>K<SUB>d</SUB>+L</NU><DE>P</DE></FR>−<RAD><RCD><FENCE>1+<FR><NU>K<SUB>d</SUB>+L</NU><DE>P</DE></FR></FENCE><SUP>2</SUP>−<FR><NU>4×L</NU><DE>P</DE></FR></RCD></RAD></FENCE>×<FR><NU>&Dgr;I</NU><DE>2</DE></FR> (Eq. 1)
where Delta I is the maximum fluorescence change, P is the initial concentration of f-heparin, f-DS, or f-FPR-thrombin, L is the total fibrinogen concentration, and a stoichiometry of 1 is assumed (28).

Determination of the Affinities of Thrombin for Heparin and DS-- The affinities of heparin or DS for thrombin were determined by monitoring changes in intrinsic thrombin fluorescence when the enzyme was titrated with heparin or DS. The initial intensity reading of 100 nM thrombin in a 2-ml quartz cuvette (Io) was determined with excitation and emission wavelengths set to 280 and 340 nm, respectively, and excitation and emission slit widths set to 6 nm. Aliquots of either heparin or DS were then added to the cuvette, and, after mixing, changes in fluorescence were monitored (I). Kd values were calculated by plotting I/Io versus glycosaminoglycan concentration and the data were fit by nonlinear regression to the equation given above.

Determination of the Affinities of HCII for Heparin, DS, and SF-- The association between HCII and either heparin, DS, or fibrin was monitored by the ligand-dependent fluorescence intensity change of anilinonaphthalene-6-sulfonic acid labeled HCII (ANS-HCII). ANS-HCII, prepared as previously described (30), was added to a concentration of 100 nM to a quartz cuvette. The initial fluorescence intensity (Io) of ANS-HCII was determined at excitation and emission wavelengths set to 280 and 437 nm, respectively, and excitation and emission slit widths set to 10 nm, and an emission filter of 290 nm. Known quantities of either heparin, DS, or SF were then added to the cuvette and, after mixing, changes in fluorescence was monitored (I). Kd values were calculated by plotting I/Io versus ligand concentration, and the data were fit by nonlinear regression to the equation given above.

Displacement of Thrombin from FM-Sepharose by HCII-- 500-µl suspensions of FM-Sepharose (9 µM FM) containing 50 nM 125I-FPR-thrombin without glycosaminoglycan or with 2.5 µM DS in TBS/0.6% PEG/0.01% Tween 20 were mixed for 2 min. The amount of unbound 125I-FPR-thrombin in the suspension after each addition of an aliquot of 80 µM HCII was determined as described above.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Comparison of the Effect of SF on Heparin- and DS-catalyzed Rates of Thrombin Inhibition by HCII-- To verify the protective effect of SF on thrombin inhibition by HCII, we determined the rates of thrombin inhibition in the absence or presence of SF and heparin. As shown in Fig. 1A, SF caused a dose-dependent decrease in the heparin-catalyzed rates of thrombin inhibition by HCII, which by two-way analysis of variance performed using Minitab (software version 11, State College, PA), was highly significant (p < 0.001). At 1 µM heparin and 4 µM SF, a maximal 240-fold decrease in the rate was observed, a value consistent with that reported previously (15). In contrast, at a concentration of 4 µM SF, a significant (p < 0.001) but modest 3-fold decrease in the DS-catalyzed rates of thrombin inhibition by HCII was observed (Fig. 1B).


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 1.   Effects of SF on the second-order rate constants for the inhibition of thrombin by heparin- or DS-catalyzed HCII. A, the second-order rate constants for inhibition of 10 nM thrombin by at least 10-fold molar excess of HCII in the presence of heparin and in the absence () or presence of 0.25 µM (black-down-triangle ) or 4 µM (black-square) SF were determined under pseudo-first-order conditions. B, the second-order rate constants for inhibition of 10 nM thrombin by 100 nM HCII in the presence of DS and in the absence () or presence of 2 µM (black-triangle) or 4 µM (black-square) SF were determined under pseudo-first-order conditions. Each point represents the mean of two determinations, and the bars represent the standard error of the mean.

Quantification of Binary Interactions That Comprise Ternary Thrombin·Fibrin·Glycosaminoglycan Complexes-- The assembly of the ternary heparin·thrombin·fibrin complex is postulated to occur through a series of binary interactions between thrombin·fibrin, thrombin·heparin, and fibrin·heparin (8, 10, 18). In this study, we determined the dissociation constants for these interactions, as well as those involving DS. The affinities of DS and heparin for thrombin were determined by monitoring changes in intrinsic protein fluorescence of thrombin when titrated with DS or heparin (not shown). DS and heparin bind saturably to thrombin with Kd values of 2600 and 116 nM, respectively (Table I). The Kd value for the thrombin·heparin interaction is in agreement with that determined by titration of ANS-labeled thrombin with increasing concentrations of heparin (Kd = 59 nM) (10).

                              
View this table:
[in this window]
[in a new window]
 
Table I
Dissociation constants for the binary interactions constituting ternary thrombin · fibrin · heparin and thrombin · fibrin · DS complexes
Kd values were determined as described under "Methods." Interactions where no binding could be detected under the given conditions are indicated.

Current evidence suggests that both heparin and DS bind to exosite II on thrombin (11-13, 31). This was confirmed in two ways. First, competitive binding studies were performed where thrombin-bound f-heparin was displaced by DS (Fig. 2). In this experiment, addition of thrombin to f-heparin resulted in an approximate 3.5% decrease in fluorescence intensity. Subsequent titration of the sample with DS resulted in a dose-dependent increase of fluorescence intensity to the value observed for f-heparin prior to binding to thrombin (I/Io of 1). Likewise, in the reciprocal experiment, the fluorescence decrease that occurred upon addition of thrombin to f-DS was negated in a dose-dependent fashion by titration with heparin (not shown). In a second approach, we used thrombin variants with impaired exosites to identify the DS binding site (not shown). DS binds to gamma -thrombin, a proteolytic derivative of alpha -thrombin lacking exosite I (11), with a 2.6-fold lower affinity than alpha -thrombin (Kd values of 6.8 µM and 2.6 µM, respectively). In contrast, DS binds RA-thrombin, a thrombin variant with three point mutations in exosite II that lower its affinity for heparin 20-fold (32), with a 7-fold lower affinity (Kd = 17 µM). These studies confirm that, like heparin, DS also binds to exosite II on thrombin, albeit with lower affinity (Table I).


View larger version (9K):
[in this window]
[in a new window]
 
Fig. 2.   Displacement of f-heparin from thrombin by DS. The fluorescence (Io) of 50 nM f-heparin was monitored at lambda ex = 492 nm and lambda em = 535 nm with an emission filter at 515 nm. Addition of 200 nM thrombin caused an approximate 3.5% decrease in intensity. The sample was then titrated with DS, and the intensity was determined after each addition (I). Values for I/Io are plotted versus DS concentration, and the line represents nonlinear regression analysis of the fit of the data to the binding isotherm equation.

The affinities of f-FPR-thrombin, f-heparin, and f-DS for fibrin were monitored by clotting varying concentrations of fibrinogen with a catalytic amount of thrombin in the presence of a fluorescently labeled ligand, and quantifying unbound ligand in the clot supernatant (not shown). As listed in Table I, f-FPR-thrombin and f-heparin bind to fibrin with Kd values of 1500 and 187 nM, respectively, values consistent with previous reports (8, 10). In contrast, f-DS does not bind to fibrin.

Both heparin and DS bind to ANS-HCII, but the affinity of heparin for HCII is 5-fold higher (13 and 71 µM, respectively). Thus, DS binds to both HCII and thrombin with lower affinity than heparin. No binding of ANS-HCII to fibrin was detected (Table I).

Effect of Heparin and DS on the Binding of 125I-FPR-thrombin to Fibrin-- It has been shown previously that heparin enhances the binding of thrombin to fibrin, an effect that occurs regardless of whether heparin has high or low affinity for antithrombin, but occurring only with heparin chains of 11,200 Da or more (8). In this study, we compared the ability of DS to promote thrombin binding to FM-Sepharose with that of heparin and low-molecular-weight heparin. As shown in Fig. 3, DS has little effect on 125I-FPR-thrombin binding to FM-Sepharose, even at concentrations up to 10 µM. In contrast, at concentrations up to 250 nM, heparin enhances 125I-FPR-thrombin binding to FM-Sepharose in a dose-dependent manner. At heparin concentrations above 250 nM, 125I-FPR-thrombin binding to fibrin monomer decreases, likely reflecting the accumulation of distinct heparin·fibrin and heparin·thrombin populations (8). When thrombin and FM-Sepharose were titrated with low-molecular-weight heparin (enoxaparin), there was only a small increase in the amount of thrombin bound, comparable to that observed with DS. Similar results were obtained with fibrin clots in place of FM-Sepharose (not shown).


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 3.   Effect of heparin or DS on the binding of 125I-FPR-thrombin to FM-Sepharose. Suspensions containing 50 nM 125I-FPR-thrombin and 9 µM FM-Sepharose in 0.5 ml were centrifuged, and 0.1-ml aliquots were counted for radioactivity to determine the percentage of 125I-FPR-thrombin bound. Aliquots of heparin (), low-molecular-weight heparin (black-triangle), or DS (open circle ) were added to the tubes, and the samples were mixed for 2 min. After each addition of glycosaminoglycan, the samples were centrifuged and the supernatants recounted. Each point represents the mean of two determinations, and the bars represent the standard error of the mean.

Incorporation of Thrombin into Ternary Glycosaminoglycan·Thrombin·Fibrin Complexes-- Our binding studies indicate that thrombin can interact with both fibrin and DS, via exosites I and II, respectively. These findings suggest that, like heparin, DS can form a three-component complex with thrombin and fibrin, even though DS does not bind fibrin. To explore this possibility, a mixture of 500 nM 125I-labeled DS and 5 µM FM-Sepharose was titrated with increasing concentrations of thrombin or gamma -thrombin (Fig. 4). After centrifugation, residual 125I-labeled DS in the supernatant was quantified and used to determine the fraction of 125I-labeled DS bound to FM-Sepharose. In the absence of thrombin, minimal amounts of 125I-labeled DS bind to FM-Sepharose. With thrombin addition, 125I-labeled DS binds to FM-Sepharose in a concentration-dependent fashion. In contrast, when gamma -thrombin, a proteolytic derivative of thrombin that lacks exosite 1, is substituted for thrombin, there is no increase in the amount of 125I-labeled DS that binds to FM-Sepharose. These data indicate that a DS·thrombin·fibrin complex can form despite the lack of direct DS·fibrin interactions.


View larger version (19K):
[in this window]
[in a new window]
 
Fig. 4.   Effect of thrombin or gamma -thrombin on the binding of 125I-labeled DS to FM-Sepharose. Binding of 500 nM 125I-labeled DS to 5 µM FM-Sepharose was determined in the presence of thrombin () or gamma -thrombin () at the indicated concentrations. After each thrombin addition, FM-Sepharose was sedimented by centrifugation, aliquots of supernatant were counted for radioactivity, and the fraction of 125I-labeled DS bound to FM-Sepharose was calculated. Each point represents the mean of at least two determinations, and the bars reflect the standard error of the mean.

Influence of Ternary Thrombin·Fibrin·Glycosaminoglycan Complex Formation on the Conformation of the Active Site of Thrombin-- Incorporation of thrombin into a ternary heparin·thrombin·fibrin complex alters the rate of thrombin-mediated hydrolysis of chromogenic substrates (9, 10, 15), suggesting that ternary complex formation induces conformational changes in the active site of thrombin that may limit its reactivity with macromolecular inhibitors (18). To determine whether thrombin in a DS·thrombin·fibrin complex also experiences conformational changes in its active site, the fluorescence of ANS-FPR-thrombin was monitored upon addition of DS and/or SF, as was described previously for heparin or SF (10). As illustrated in Fig. 5A, addition of 310 nM SF or 100 nM heparin to 140 nM ANS-FPR-thrombin produces a 19 and 48% increase in fluorescence, respectively, compared with the fluorescence of ANS-thrombin alone. When 100 nM heparin is added to the ANS-FPR-thrombin/SF mixture, however, there is an 86% increase in fluorescence. The observation that the addition of both SF and heparin produces a greater change in the emission spectrum of ANS-FPR-thrombin than the two components alone is in agreement with a previous report by Hogg et al. (10) and suggests that formation of the ternary heparin· thrombin·fibrin complex induces conformational changes in the active site of thrombin beyond those produced by formation of binary thrombin·fibrin or thrombin·heparin complexes. In contrast to the results obtained with heparin, the addition of 3 µM DS, a concentration above the Kd value for the DS·thrombin interaction (Table I), to either ANS-FPR-thrombin alone or to the ANS-FPR-thrombin/SF mixture has minimal effect on the emission spectra (Fig. 5B). These findings suggest that, unlike heparin, DS does not induce conformational changes in the active site environment of thrombin in the absence or presence of fibrin.


View larger version (11K):
[in this window]
[in a new window]
 
Fig. 5.   Influence of SF and/or heparin or DS on the emission spectrum of ANS-thrombin. A, the emission spectrum of ANS-thrombin, at excitation wavelength of 334 nm, was monitored from 380 to 580 nm in the absence () or presence of SF (black-square), heparin (triangle ), or the combination of SF and heparin (diamond ). B, the emission spectrum of ANS-thrombin was monitored in the absence () or presence of SF (black-square), DS (down-triangle), or the combination of SF and DS (open circle ). For clarity, only every 15th point of each spectrum is plotted.

Effect of Heparin and Low-molecular-weight Heparin on the Rate of Inhibition of Fibrin-bound Thrombin by the DS·HCII Complex-- Although fibrin-bound thrombin is susceptible to inactivation by the DS·HCII complex (Fig. 1), we predicted that heparin, by virtue of its higher affinity for both fibrin and thrombin than DS, would impair DS activity by bridging thrombin to fibrin, thereby enhancing the fibrin·thrombin interaction. As a control, we used low-molecular-weight heparin, because only heparin chains of >11.2 kDa are of sufficient length to bridge thrombin to fibrin (8). In the presence of 4 µM SF, heparin concentrations of 0.1 µM or higher cause a decrease in the 3.3 µM DS-catalyzed rate of thrombin inhibition by HCII (Fig. 6). In contrast, a low-molecular-weight heparin, enoxaparin, has no effect on the rate of inhibition of fibrin-bound thrombin by the DS·HCII complex. Neither heparin nor low-molecular-weight heparin influenced the DS-catalyzed rate of thrombin inhibition in the absence of SF (data not shown).


View larger version (13K):
[in this window]
[in a new window]
 
Fig. 6.   Effect of heparin or low-molecular-weight heparin on DS-catalyzed rates of thrombin inhibition by HCII in the presence of SF. The second-order rate constants for the inhibition of 5 nM thrombin by HCII with 3.3 µM DS in the presence of 4 µM SF were determined under pseudo first-order conditions. Experiments were repeated in the presence of increasing concentrations of heparin (open circle ) or low-molecular-weight heparin (). Each point represents the mean of at least two determinations, and the bars represent the standard error.

Displacement of IIa from FM-Sepharose by HCII-- Because catalysis of thrombin inhibition by HCII is not impaired by fibrin in the presence of DS, exosite I on thrombin must be accessible to the DS·HCII complex even though thrombin binds to fibrin via this site. This observation predicts that the DS·HCII complex is capable of displacing thrombin from fibrin by binding the amino-terminal tail of HCII to exosite I of thrombin. This was tested by monitoring the amount of 125I-FPR-thrombin displaced from FM-Sepharose by increasing concentrations of HCII in the absence or presence of DS (Fig. 7). HCII alone, at concentrations up to three times physiological concentration, had limited capacity to displace thrombin from FM-Sepharose. However, in the presence of 2.5 µM DS, dose-dependent displacement of thrombin by HCII was observed. Maximal displacement was achieved with physiological concentrations of HCII, with half-maximal effect at about 250 nM HCII. Thus, the amino terminus of HCII is able to compete effectively with fibrin for binding to thrombin exosite I. 


View larger version (15K):
[in this window]
[in a new window]
 
Fig. 7.   Displacement of thrombin from FM-Sepharose by HCII in the absence or presence of DS or heparin. Suspensions of 10 µM FM-Sepharose containing 50 nM 125I-FPR-thrombin in the absence (open circle ) or presence of 2.5 µM DS () were prepared. The amount of 125I-FPR-thrombin not bound to FM-Sepharose, determined by measuring radioactivity of aliquots of the supernatant after centrifugation of the suspension, was used to calculate the fraction of 125I-FPR-thrombin bound. Aliquots of HCII were added to the suspensions and the amount 125I-FPR-thrombin bound was determined after each addition.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

In this study, we demonstrate that fibrin-bound thrombin is readily inhibited by the DS·HCII complex, but not by the heparin·HCII complex, even though heparin and DS demonstrate comparable catalysis of HCII in the absence of fibrin (Fig. 1). The resistance of fibrin-bound thrombin to inhibition by the heparin·HCII complex is a consequence of formation of a ternary heparin·thrombin·fibrin complex (15). This ternary complex forms as a result of mutual binary interactions between each of the three components, resulting in increased affinity of each of the individual interactions (10, 18). Formation of this ternary complex protects thrombin from inhibition by heparin·HCII by reducing access of the amino terminus of HCII to exosite I on thrombin, impairing the ability of HCII-bound heparin to bridge HCII to exosite II on thrombin, and inducing allosteric changes in the active site of thrombin that may limit its reactivity with HCII (10, 15).

Like heparin, DS binds to exosite II on thrombin, even when thrombin is fibrin-bound (Fig. 2). However, DS and heparin are distinguished by the fact that only heparin binds fibrin (Table I). With high affinity for thrombin and fibrin, heparin augments exosite I-mediated binding of thrombin to fibrin, impairing the ability of HCII to bind and inhibit thrombin (Fig. 3). Because DS does not heighten the thrombin·fibrin interaction, the amino terminus of DS-activated HCII retains access to exosite I on thrombin. The failure of DS to induce a conformational change in the active site of thrombin (Fig. 5B) may also permit reactivity of HCII with fibrin-bound thrombin. These results confirm the hypothesis that all three binary interactions (thrombin·fibrin, thrombin·glycosaminoglycan, glycosaminoglycan·fibrin) within the ternary complex are integral to convey protection of fibrin-bound thrombin from inhibition by heparin-catalyzed inhibitors (15).

Heparin compromises the DS-catalyzed rate of thrombin inhibition by HCII in the presence of fibrin (Fig. 6). This reduction in rate is consistent with the formation of a ternary thrombin·fibrin·heparin complex. Heparin can bridge thrombin to fibrin in the presence of DS, because the affinity of heparin for thrombin is higher than that of DS (Table I). In contrast, low-molecular-weight heparin (enoxaparin) does not reduce the DS-catalyzed rate of thrombin inhibition by HCII, because only heparin chains greater than 11.2 kDa are of sufficient length to bind simultaneously to thrombin and fibrin (8).

The DS·HCII complex displaces thrombin from FM-Sepharose with an IC50 value of 0.17 µM (Fig. 7). This value reflects the ability of the amino terminus of DS-activated HCII to bind to thrombin exosite I. A previous study determined that a 22-residue peptide, corresponding to amino acids 54-75 of HCII, inhibited the clotting activity of thrombin with an IC50 of 28 µM (33). The lower IC50 value with intact HCII suggests that there are additional interactions with thrombin provided by the remainder of the amino terminus or the body of the HCII molecule. A homologous peptide derived from hirudin residues 54-66 inhibited thrombin clotting activity with an IC50 of 0.8 µM (33). This compares with the Ki value of 0.6 µM derived for the initial encounter of intact hirudin with thrombin (34). Thus, in addition to its ability to inhibit fibrin-bound thrombin, the DS·HCII complex displaces thrombin from fibrin allowing both HCII and antithrombin to inhibit thrombin. A similar displacement role for the hirudin53-64 peptide has been proposed (35).

Our observation that fibrin-bound thrombin is susceptible to inactivation by the DS·HCII complex suggests that DS should be effective for the prevention and treatment of thrombosis. In a randomized trial comparing subcutaneous DS with low dose subcutaneous heparin for thromboprophylaxis in patients undergoing general surgical procedures, both agents had comparable efficacy (22). More recently, DS was shown to be more effective than heparin at preventing postoperative venous thrombosis in patients undergoing general surgical procedures (36). Studies in rabbits suggest that DS suppresses thrombus accretion to a greater extent than heparin when the two agents are given in doses that have the same inhibitory activity against thrombin in vitro (25).

DS produces only minimal inhibition of platelet and fibrin deposition in a high shear, arterial-type thrombosis model in baboons (37). The limited efficacy of DS in this setting may reflect the fact that DS only inhibits thrombin and has no effect on factor Xa-mediated thrombin generation, an important contributor to thrombus growth (38). Consequently, if selective thrombin inhibitors are used as monotherapy for treatment of arterial thrombosis, high concentrations may be necessary to prevent thrombus propagation. This concept is supported by our recent studies demonstrating that both DS and hirudin, agents that inhibit fibrin-bound thrombin, as well as free thrombin, are limited in their ability to block clotting in a thrombogenic extracorporeal circuit (30). In contrast, Vasoflux, a drug that not only inhibits fibrin-bound thrombin but also blocks factor Xa generation, prevents clotting in the circuit (30). These findings raise the possibility that adding heparin to DS may improve its efficacy, because heparin will block factor Xa-mediated thrombin generation. Our observation that unfractionated heparin compromises the rate of thrombin inhibition by the DS·HCII complex, whereas low-molecular-weight heparin does not (Fig. 6), suggests that low-molecular-weight heparin may be a better adjunct to DS than unfractionated heparin. The observation that DS and low-molecular-weight heparin display additive anticoagulant activity in vitro provides further support for this approach (39).

In summary, our results indicate that fibrin-bound thrombin is readily inhibited by the DS·HCII complex because, unlike heparin, DS does not bridge thrombin to fibrin. Although DS and heparin can form thrombin·fibrin·glycosaminoglycan complexes, the additional heparin·fibrin interaction strengthens the ternary complex, thereby limiting accessibility of thrombin exosites and inducing conformational changes in the active site of thrombin. These findings reveal that resistance of thrombin to inhibition by serpins results from a glycosaminoglycan·fibrin interaction, as well as interactions between thrombin·fibrin and thrombin·glycosaminoglycan. These mechanistic insights also demonstrate the advantages of glycosaminoglycans whose activities are not compromised by fibrin.

    FOOTNOTES

* This work was supported in part by grants-in-aid from the Medical Research Council of Canada (MT-3992), the Heart and Stroke Foundation of Ontario (T-2268 and MT-3664), and the Ontario Research and Development Challenge Fund.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger Recipient of a Research Fellowship from the Heart and Stroke Foundation of Canada.

§ Recipient of a Career Investigator Award from the Heart and Stroke Foundation of Canada and holder of the Heart and Stroke Foundation of Ontario/J. Fraser Mustard Chair in Cardiovascular Research and the Canada Research Chair in Thrombosis at McMaster University. To whom correspondence should be addressed: Henderson Research Center, 711 Concession St., Hamilton, Ontario L8V 1C3, Canada. Tel.: 905-574-8550; Fax: 905-575-2646; E-mail: jweitz@ thrombosis.hhscr.org.

Published, JBC Papers in Press, April 9, 2001, DOI 10.1074/jbc.M010584200

    ABBREVIATIONS

The abbreviations used are: HCII, heparin cofactor II; ANS, anilinonaphthalene-6-sulfonic acid; DS, dermatan sulfate; f, fluorescein-labeled; SF, soluble fibrin; FM, fibrin monomer; FITC, fluorescein-5'-isothiocyanate; FPR, D-Phe-Pro-Arg; FPRCK, D-Phe-Pro-Arg-chloromethyl ketone; GPRP-NH2, Gly-Pro-Arg-Pro-amide; tGPR-pNA, N-p-tosyl-Gly-Pro-Arg-p-nitroanilide acetate; ATA, N-(acetylthio)acetyl; TBS, Tris-buffered saline; PEG, polyethylene glycol.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Rosenberg, R. D. (1987) in Haemostasis and Thrombosis: Basic Principles and Clinical Practice (Colman, R. W. , Hirsh, J. , Marder, V. J. , and Salzman, E. W., eds) , pp. 1377-1382, J. B. Lippincott, Philadelphia
2. Popma, J. J., Ohman, E. M., Weitz, J., Lincoff, A. M., Harrington, R. A., and Berger, P. (2001) Chest 119, 321S-336S[Free Full Text]
3. The International Study Group. (1990) Lancet 336, 71-75[Medline] [Order article via Infotrieve]
4. ISIS-3 Collaborative Group. (1992) Lancet 339, 753-770[Medline] [Order article via Infotrieve]
5. Collins, R., MacMahon, S., Flather, M., Baigent, C., Remvig, L., Mortensen, S., Appleby, P., Godwin, J., Yusuf, S., and Peto, R. (1996) Br. Med. J. 313, 652-659[Abstract/Free Full Text]
6. Hogg, P. J., and Jackson, C. M. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 3619-3623[Abstract]
7. Weitz, J. I., Hudoba, M., Massel, D., Maraganore, J., and Hirsh, J. (1990) J. Clin. Invest. 86, 385-391[Medline] [Order article via Infotrieve]
8. Hogg, P. J., and Jackson, C. M. (1990) J. Biol. Chem. 265, 241-247[Abstract/Free Full Text]
9. Hogg, P. J., and Jackson, C. M. (1990) J. Biol. Chem. 265, 248-255[Abstract/Free Full Text]
10. Hogg, P. J., Jackson, C. M., Labanowski, J. K., and Bock, P. E. (1996) J. Biol. Chem. 271, 26088-26095[Abstract/Free Full Text]
11. Church, F. C., Pratt, C. W., Noyes, C. M., Kalayanamit, T., Sherrill, G. B., Tobin, R. B., and Meade, J. B. (1989) J. Biol. Chem. 264, 18419-18425[Abstract/Free Full Text]
12. Gan, Z. R., Li, Y., Chen, Z., Lewis, S. D., and Shafer, J. A. (1994) J. Biol. Chem. 269, 1301-1305[Abstract/Free Full Text]
13. Sheehan, J. P., and Sadler, J. E. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 5518-5522[Abstract]
14. Odrljin, T., Shainoff, J. R., Lawrence, S. O., and Simpson-Haidaris, P. J. (1996) Blood 88, 2050-2061[Abstract/Free Full Text]
15. Becker, D. L., Fredenburgh, J. C., Stafford, A. R., and Weitz, J. I. (1999) J. Biol. Chem. 274, 6226-6233[Abstract/Free Full Text]
16. Tollefsen, D. M. (1995) Thromb. Haemost. 74, 1209-1214[Medline] [Order article via Infotrieve]
17. Liaw, P. C., Austin, R. C., Fredenburgh, J. C., Stafford, A. R., and Weitz, J. I. (1999) J. Biol. Chem. 274, 27597-27604[Abstract/Free Full Text]
18. Hogg, P. J., and Bock, P. E. (1997) Thromb. Haemost. 77, 424-433[Medline] [Order article via Infotrieve]
19. Merton, R. E., and Thomas, D. P. (1987) Thromb. Haemost. 58, 839-842[Medline] [Order article via Infotrieve]
20. Van Ryn-McKenna, J., Ofosu, F. A., Gray, E., Hirsh, J., and Buchanan, M. R. (1989) Ann. N. Y. Acad. Sci. 556, 304-312[Abstract]
21. Lane, D. A., Ryan, K., Ireland, H., Curtis, J. R., Nurmohamed, M. T., Krediet, R. T., Roggekamp, M. C., Stevens, P., and ten Cate, J. W. (1992) Lancet 339, 334-335[Medline] [Order article via Infotrieve]
22. Prandoni, P., Meduri, F., Cuppini, S., Toniato, A., Zangrandi, F., Polistena, P., Gianese, F., and Maffei Faccioli, A. (1992) Br. J. Surg. 79, 505-509[Medline] [Order article via Infotrieve]
23. Agnelli, G., Cosmi, B., Di Filippo, P., Ranucci, V., Veschi, F., Longetti, M., Renga, C., Barzi, F., Gianese, F., and Lupattelli, L. (1992) Thromb. Haemost. 67, 203-208[Medline] [Order article via Infotrieve]
24. Bendayan, P., Boccalon, H., Dupouy, D., and Boneu, B. (1994) Thromb. Haemost. 71, 576-580[Medline] [Order article via Infotrieve]
25. Okwusidi, J. I., Anvari, N., Kulczycky, M., Blajchman, M. A., Buchanan, M. R., and Ofosu, F. A. (1991) J. Lab. Clin. Med. 117, 359-364[Medline] [Order article via Infotrieve]
26. Kawasaki, K., Hirase, K., Miyano, M., Tsuji, T., and Iwamoto, M. (1992) Chem. Pharm. Bull. (Tokyo) 40, 3253-3260[Medline] [Order article via Infotrieve]
27. Olson, S. T., Björk, I., and Shore, J. D. (1993) Methods Enzymol. 222, 525-560[Medline] [Order article via Infotrieve]
28. Fredenburgh, J. C., Stafford, A. R., and Weitz, J. I. (1997) J. Biol. Chem. 272, 25493-25499[Abstract/Free Full Text]
29. Nagasawa, K., and Uchiyama, H. (1978) Biochim. Biophys. Acta 544, 430-440[Medline] [Order article via Infotrieve]
30. Weitz, J. I., Young, E., Johnston, M., Stafford, A. R., Fredenburgh, J. C., and Hirsh, J. (1999) Circulation 99, 682-689[Abstract/Free Full Text]
31. Sheehan, J. P., Tollefsen, D. M., and Sadler, J. E. (1994) J. Biol. Chem. 269, 32747-32751[Abstract/Free Full Text]
32. Ye, J., Rezaie, A. R., and Esmon, C. T. (1994) J. Biol. Chem. 269, 17965-17970[Abstract/Free Full Text]
33. Hortin, G. L., Tollefsen, D. M., and Benutto, B. M. (1989) J. Biol. Chem. 264, 13979-13982[Abstract/Free Full Text]
34. Jackman, M. P., Parry, M. A. A., Hofsteenge, J., and Stone, S. R. (1992) J. Biol. Chem. 267, 15375-15383[Abstract/Free Full Text]
35. Naski, M. C., Fenton, J. W. I., Maraganore, J. M., Olson, S. T., and Shafer, J. A. (1990) J. Biol. Chem. 265, 13484-13489[Abstract/Free Full Text]
36. Di Carlo, V., Agnelli, G., Prandoni, P., Coccheri, S., Gensini, G. F., Gianese, F., and Mannucci, P. M. (1999) Thromb. Haemost. 82, 30-34[Medline] [Order article via Infotrieve]
37. Cadroy, Y., Hanson, S. R., and Harker, L. A. (1993) Arterioscler. Thromb. 13, 1213-1217[Abstract]
38. Eisenberg, P. R., Siegel, J. E., Abendschein, D. R., and Miletich, J. P. (1993) J. Clin. Invest. 91, 1877-1883[Medline] [Order article via Infotrieve]
39. Cosmi, B., Agnelli, G., Young, E., Hirsh, J., and Weitz, J. (1993) Thromb. Haemost. 70, 443-447[Medline] [Order article via Infotrieve]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.